Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 275-912-7 | CAS number: 71720-84-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Oral LD50 (female) > 2000 mg/kg body weight
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From May 25 to June 15, 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- 17 December 2001
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Version / remarks:
- May 2008
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: iIn-house bred animals.
- Females: nulliparous and non-pregnant.
- Age at study initiation: 9 to 10 weeks.
- Weight at study initiation: 160.64 to 167.67 g
- Fasting period before study: animals were fasted overnight (16 to 18 hours) prior to dosing; ater was provided ad libitum during fasting period.
- Housing: animals were housed in standard polypropylene cage (430 x 285 x 150 mm) with stainless steel mesh top grill having facilities for holding pelleted feed and drinking water in water bottle fitted with stainless steel sipper tube; three per cage.
- Diet: Altromin Maintenance diet for rats and mice 1324 manufactured by Altromin Spezialfutter GmbH & Co. KG was provided, ad libitum.
- Water: ad libitum.
- Acclimation period: healthy young adult animals used for Step-I and Step-I confirmation were acclimatized for five and seven days respectively to laboratory condition prior to treatment and were observed for clinical signs once daily.
- Health check: veterinary examination of all the animals was performed on the day of receipt and on 5th day of acclimatization.
ENVIRONMENTAL CONDITIONS
- Temperature: 19.6 to 22.9 °C
- Humidity: 43 % to 6 5%
- Air changes:12 to 15 air changes per hour.
- Photoperiod: 12 hours fluorescent light and 12 hours dark cycle. - Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- Dose formulations was calculated by the active ingredient content.
- Concentration: 200 (mg/ml)
- Dose volume: 10 ml/kg body weight - Doses:
- 2000 mg a.i./kg body weight (corresponding to 2520 mg/kg body weight)
- No. of animals per sex per dose:
- 3 female animals per step
- Details on study design:
- - Study Design: the animals were dosed in a stepwise procedure with three female animals per step. Since no clinical signs of toxicity and mortality was observed at 2000 mg/kg body weight in Step-I, the sequential Step-I confirmation was conducted using three more female rats treated at the same dose level.
- Duration of observation period following administration: 14 days
- Frequency of observations: all the animals were observed for clinical signs of toxicity and mortality at 30 to 40 min, 1 hr (±10 mins), 2 hrs (±10 mins), 3 hrs (±10 mins) and 4 hrs (±10 mins) post dosing on day 1 and once daily thereafter for clinical signs of toxicity and twice daily for mortality during the 14 days observation period. Observations included changes in skin, fur, eyes and mucous membranes and also respiratory, circulatory, autonomic and central nervous systems and somatomotor activity and behaviour pattern.
- Frequency of weighing: individual animal body weight was recorded at receipt, on day 1 (before test item administration) and on day 8 and 15 during the observation period.
- Necropsy of survivors performed: at the end of observation period, all the animals were sacrificed under carbon dioxide anaesthesia, subjected to necropsy and a complete gross pathological examination. - Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- act. ingr.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Mortality:
- No deaths occurred.
- Clinical signs:
- other: No clinical signs of toxicity and mortality was observed in the animals dosed with 2000 mg/kg body weight in both Step-I and Step-I confirmation.
- Gross pathology:
- No gross pathological changes were observed in any of the animals dosed at 2000 mg/kg body weight in both Step-I and Step-I confirmation.
- Interpretation of results:
- other: not classified, according to the CLP Regulation (EC) 1272/2008
- Conclusions:
- LD50 (female) > 2000 mg/kg body weight
- Executive summary:
The test item was evaluated for acute oral toxicity in Sprague Dawley rats as per OECD Guideline No. 423.
A starting dose of 2000 mg/kg body weight was selected.
A total of 09 females (3 females each for each Step-I and Step-I confirmation) were used for the experiment. All the animals of Step-I and Step-I confirmation were administered with 2000 mg/kg body weight of the test item through oral route.
All the animals were observed for clinical signs of toxicity and mortality at 30 to 40 min, 1 hr, 2 hrs, 3 hrs and 4 hrs post dosing on day 1 and once daily thereafter for clinical signs of toxicity and twice daily for mortality during the 14 days observation period. Body weight was recorded on day 1 before test item administration and on day 8 and 15 during the observation period. At the end of observation period, all the surviving animals were sacrificed under carbon dioxide anaesthesia, subjected to necropsy and gross pathology examination.
In Step-I and Step-I confirmation, the animals dosed with 2000 mg/kg body weight did not reveal any clinical signs of toxicity and mortality. No changes were observed in body weight and percent change in body weight with respect to day 1 at 2000 mg/kg body weight. All the animals revealed physiologically normal increase in the body weight.
No gross pathological changes were observed in any of the animals dosed at 2000 mg/kg body weight.
Conclusion
LD50 (female) > 2000 mg/kg body weight
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
Additional information
ACUTE TOXICITY - ORAL ROUTE
The test item was evaluated for acute oral toxicity in Sprague Dawley rats as per OECD Guideline No. 423. A starting dose of 2000 mg/kg body weight was selected. 3 females each for each Step-I and Step-I confirmation were used for the experiment. All the animals of Step-I and Step-I confirmation were administered with 2000 mg/kg body weight of the test item through oral route.
In Step-I and Step-I confirmation, the animals dosed with 2000 mg/kg body weight did not reveal any clinical signs of toxicity and mortality. No changes were observed in body weight and percent change in body weight with respect to day 1 at 2000 mg/kg body weight. All the animals revealed physiologically normal increase in the body weight. No gross pathological changes were observed in any of the animals dosed at 2000 mg/kg body weight.
ACUTE TOXICITY - INHALATION ROUTE
No acute toxicity studies by inhalation route are available on Acid Green 040.
Nevertheless, because of the physical state of the substance inhalation is not expected to be an appropriate route of exposure. Particle size distribution showed that the ca 92 % of particles has a diameter greater than 45 μm. Thus, most of the Acid Green 040 particles are expected to remain in the upper respiratory tract, which is characterized by efficacious defence mechanisms able to remove them; therefore, respirable particles, able to enter the deepest part of the lung, the non-ciliated alveoli (i.e. D50 of 4 μm), can be considered a minimal portion.
ACUTE TOXICITY - DERMAL ROUTE
Because of the physical/chemical properties of the substance, also the dermal absorption is expected as negligible.
According to the Commission Regulation (EU) 2016/863, amending Annexes VII and VIII to REACH Regulation (EC) 1907/2006, testing by the dermal route does not need to be conducted if no systemic effects have been observed in in vivo studies with dermal exposure (e.g. skin irritation, skin sensitisation). Furthermore, it is explained that recent scientific analysis of available data from in vivo acute toxicity studies has shown that substances that are not toxic via the oral route may be expected with high certainty to be also non-toxic via the dermal route.
The amendment is the consequence of studies and scientific debates. In particular, the 15th Meeting of Competent Authorities for REACH and CLP (CARACAL, 2014) concluded that information on acute dermal toxicity can be avoided for substances that have shown no toxicity in acute oral toxicity test up to the limit dose of 2000 mg/kg bw.
In the case of Acid Orange 040, no signs of systemic impairments were found during the in vivo acute oral toxicity test; in addition, the substance resulted to be non skin irritating in rabbits and it can be considered as non-skin sensitising, based on the available data on the structural analogous (the read across approach can be considered as appropriate and suitable; details about the approach are reported into the related skin sensitisation endpoint record).
Justification for classification or non-classification
According to the CLP Regulation (EC) No 1272/2008, 3.1 Acute toxicity section, substances can be allocated to one of four toxicity categories based on acute toxicity by the oral, dermal or inhalation route according to the numeric criteria. Acute toxicity values are expressed as (approximate) LD50 (oral, dermal) or LC50 (inhalation) values or as acute toxicity estimates (ATE).
The oral LD50 value was established to be greater than 2000 mg/kg body weight, therefore the test substance is out of any classification limit for acute oral toxicity (oral acute toxicity category 4: 300 < ATE ≤ 2000 mg/kg bw).
In conclusion, the test substance does not meet the criteria to be classified for oral acute toxicity, according to the CLP Regulation (EC) No 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.